{
  "id": 10602661,
  "title": "Why is Chugai Pharmaceutical stock sliding today?",
  "url": "https://urgent.news/2026/09/29/why-is-chugai-pharmaceutical-stock-sliding-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T03:51:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-chugai-pharmaceutical-stock-sliding-today-93CH-4921541"
  },
  "original_language": "en",
  "account": "Chugai Pharmaceutical shares experienced a 2.5% decline on Tuesday, closing at ¥6,203, following the company's announcement that it would halt the development of GYM329 obesity drugs and return all licensing rights to Roche. This decision resulted from the Phase II trial's failure to demonstrate clinically meaningful weight loss, exacerbating existing concerns arising from Chugai's second-quarter results. These results fell short of market expectations, with core operating profit 5% below consensus, Hemlibra export revenues lagging, and Foundayo royalties underperforming. The stock's recent decline from its 52-week high of ¥10,700 further added to the pressure. Investors remain cautious ahead of the upcoming earnings report on October 27, 2026, as the broader Nikkei 225 index also dipped 1% on the same day.",
  "summary": null,
  "key_points": [
    "Chugai Pharmaceutical halts GYM329 development",
    "Phase II trial fails to show clinically meaningful weight loss",
    "Second-quarter results miss market expectations"
  ],
  "editors_take": "The halt in GYM329 obesity drug development and weak quarterly results have heightened investor concerns, contributing to Chugai Pharmaceutical's stock decline amid a cautious market ahead of its earnings report.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}